查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1344323

癌症個人化醫療市場：按產品、最終用戶：2023-2032 年全球機會分析與產業預測

Personalized Cancer Medicine Market By Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), By End User (Hospitals and clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 209 Pages | 商品交期: 2-3個工作天內

價格

2022年癌症個人化醫療市值為1799.9億美元，預計2023年至2032年複合年增長率為10.9%，到2032年達到5072億美元。

個人化癌症醫學市場-IMG1

癌症個人化醫療市場的成長受到多種因素的推動，包括癌症盛行率的上升以及由此帶來的對有效治療方案的需求不斷增長。這是一個重要因素。 精準醫學已成為一種有前途的癌症治療方法，推動了其採用和成長。 此外，人口老化也是推動精準醫療需求的因素之一。 人口老化更有可能罹患癌症，從而產生了更多的潛在患者。 此外，生物技術和基因工程的進步使得更有針對性和個性化的癌症治療方法的開發成為可能，從而推動了市場的成長。 此外，個人化藥物在臨床試驗中顯示出有希望的結果，導致研發活動投資增加。

此外，主要市場參與者採取的更多關鍵策略（例如產品發布、協議和聯盟）將進一步推動預測期內的市場成長。 例如，2021年2月，Qiagen和生物技術公司Inovio Pharmaceuticals宣佈建立新的基礎合作夥伴關係，開發基於下一代定序（NGS）技術的液體活檢伴隨診斷產品，以補充Inovio的療法。將擴大他們的合作夥伴關係。

此外，越來越多的監管審批也為市場成長提供了機會。 例如，2021 年 10 月，全球製藥和診斷領域的先驅 F. Hoffmann-La Roche AG 在非小細胞肺癌 (NSCLC) 中推出了 VENTANA PD-L1 (SP263) 檢測，作為 Tecentriq 的伴隨診斷。美國食品藥品監察管理局（FDA）批准。 因此，領先製造商採用此類策略可能會增加個人化醫療領域的需求和採用，為市場成長提供利潤豐厚的機會。

然而，個人化醫療的高成本正在阻礙個人化醫療市場的成長。 高昂的診斷和治療費用使經濟困難的患者無法承擔，並限制了發展中地區的市場成長。 此外，許多患者對個人化醫療概念缺乏了解也是市場的限制因素。 另一方面，政府和非政府組織可能會提高公眾對先進醫療保健選擇的認識，並增加個人化癌症藥物的採用，從而推動預測期內的市場擴張。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 癌症盛行率不斷上升
      • 對理想治療藥物的需求不斷增加
      • 更多採用基於人工智慧 (AI) 的診斷
    • 抑制因素
      • 個人化醫療成本高昂
      • 有限的報銷和承保範圍
    • 機會
      • 增加個人化癌症醫學的研發活動
  • 新冠肺炎 (COVID-19)：市場影響分析

第 4 章癌症個人化醫療市場：副產品

  • 摘要
  • 治療藥物
  • 診斷劑

第 5 章癌症個人化醫療市場：依最終使用者劃分

  • 摘要
  • 醫院/診所
  • 其他

第6章個人化癌症藥物市場：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳大利亞
    • 其他亞太地區
  • 拉丁美洲
    • 拉丁美洲
    • 中東/非洲

第7章競爭態勢

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022 年主要公司的定位

第8章公司簡介

  • Abbott Laboratories
  • ARIEL Precision Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • General Electric
  • Aadi Bioscience, Inc.
  • Illumina, Inc.
  • Qiagen NV.
  • Novartis AG
  • Thermo Fisher Scientific Inc.
  • Bristol-Myers Squibb Company
Product Code: A13364

According to a new report published by Allied Market Research, titled, "Personalized Cancer Medicine Market," The personalized cancer medicine market was valued at $179.99 billion in 2022, and is estimated to reach $507.2 billion by 2032, growing at a CAGR of 10.9% from 2023 to 2032.

Personalized Cancer Medicine Market - IMG1

The personalized cancer medicine market growth is being driven by several key factors such as the increase in prevalence of cancer, resulting in a greater demand for effective treatment options. Precision medicine has emerged as a promising approach for treating cancer, thus driving its adoption and growth. In addition, the aging population is another factor that drives the demand for precision medicine. The geriatric population is more prone to developing cancer, creating a larger pool of potential patients. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized cancer therapies, which are likely to drive the market growth. In addition, personalized medicines have shown promising results in clinical trials, leading to increased investment in research and development activities.

Moreover, the rise in key strategies adopted by the key market players such as product launch, agreement, and collaborations further drive the growth of the market during the forecast period. For instance, on February 2021, Qiagen and Inovio Pharmaceuticals, a biotechnology company announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

Furthermore, a rise in approvals from regulatory organizations further provides opportunity for market growth. For instance, on October 2021, F. Hoffmann-La Roche AG , a global pioneer in pharmaceuticals and diagnostics, received U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of personalized medicine arena and provide lucrative opportunity to market growth.

However, the high cost of personalized medicines hinders the growth of the personalized medicine market. High cost of diagnosis and treatment makes it inaccessible for the patients with poor financial conditions and restrains the market in developing regions. Furthermore, many patients are unaware about the concept of personalized medicines, which acts as a restrain to the market. On the other hand, government and non-government organizations create awareness about the advanced healthcare options among the population, which may increase the adoption of personalized cancer medicines, thus, driving the market expansion during the forecast period.

The personalized cancer medicine market is segmented into product, end user, and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. By end user, the market is bifurcated into hospitals & clinics and others. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).

Major key players that operate in the global personalized cancer medicine market are Abbott Laboratories, ARIEL Precision Medicine, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, Inc, Aadi Bioscience, Inc., Illumina, Inc., Qiagen, Novartis AG, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company. The key players operating in the market have adopted product approval, agreement, partnership, product launch, and collaboration as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized cancer medicine market analysis from 2022 to 2032 to identify the prevailing personalized cancer medicine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the personalized cancer medicine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global personalized cancer medicine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics

By End User

  • Hospitals and clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Aadi Bioscience, Inc.
    • Abbott Laboratories
    • ARIEL Precision Medicine, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • General Electric
    • Illumina, Inc.
    • Novartis AG
    • Qiagen NV.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cancer
      • 3.4.1.2. Increase in demand for ideal therapeutics for treatment
      • 3.4.1.3. Rise in adoption of Artificial Intelligence (AI) based diagnosis
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of personalized medicine
      • 3.4.2.2. Limited Reimbursement and coverage
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities in personalized cancer medicine
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Personalized Medicine Therapeutics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Personalized Medicine Diagnostics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PERSONALIZED CANCER MEDICINE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals and clinics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PERSONALIZED CANCER MEDICINE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Product
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Product
      • 6.2.4.1.3. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Product
      • 6.2.4.2.3. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Product
      • 6.2.4.3.3. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Product
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Product
      • 6.3.4.1.3. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Product
      • 6.3.4.2.3. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Product
      • 6.3.4.3.3. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Product
      • 6.3.4.4.3. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Product
      • 6.3.4.5.3. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Product
      • 6.3.4.6.3. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Product
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Product
      • 6.4.4.1.3. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Product
      • 6.4.4.2.3. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Product
      • 6.4.4.3.3. Market size and forecast, by End User
      • 6.4.4.4. Rest of Asia-Pacific
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Product
      • 6.4.4.4.3. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Product
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Latin America
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Product
      • 6.5.4.1.3. Market size and forecast, by End User
      • 6.5.4.2. Middle East And Africa
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Product
      • 6.5.4.2.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. ARIEL Precision Medicine, Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. General Electric
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Aadi Bioscience, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Illumina, Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Qiagen NV.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Thermo Fisher Scientific Inc.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 02. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 03. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 04. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 05. PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 06. PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 07. PERSONALIZED CANCER MEDICINE MARKET, BY REGION, 2022-2032 ($BILLION)
  • TABLE 08. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 09. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 10. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 11. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 12. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 13. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 14. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 15. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 16. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 17. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 18. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 19. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 20. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 21. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 22. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 23. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 24. UK PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 25. UK PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 26. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 27. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 28. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 29. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 30. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 31. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 32. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 33. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 34. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 35. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 36. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 37. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 38. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 39. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 40. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 41. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 42. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 43. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 44. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 45. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 46. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 47. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 48. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 49. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 50. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 51. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 52. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 53. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 54. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
  • TABLE 55. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
  • TABLE 56. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
  • TABLE 57. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
  • TABLE 58. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 59. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 60. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 61. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 62. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 63. GENERAL ELECTRIC: KEY EXECUTIVES
  • TABLE 64. GENERAL ELECTRIC: COMPANY SNAPSHOT
  • TABLE 65. GENERAL ELECTRIC: SERVICE SEGMENTS
  • TABLE 66. GENERAL ELECTRIC: PRODUCT PORTFOLIO
  • TABLE 67. GENERAL ELECTRIC: KEY STRATERGIES
  • TABLE 68. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
  • TABLE 69. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
  • TABLE 70. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
  • TABLE 71. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
  • TABLE 72. AADI BIOSCIENCE, INC.: KEY STRATERGIES
  • TABLE 73. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 74. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 75. ILLUMINA, INC.: PRODUCT SEGMENTS
  • TABLE 76. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 77. ILLUMINA, INC.: KEY STRATERGIES
  • TABLE 78. QIAGEN NV.: KEY EXECUTIVES
  • TABLE 79. QIAGEN NV.: COMPANY SNAPSHOT
  • TABLE 80. QIAGEN NV.: PRODUCT SEGMENTS
  • TABLE 81. QIAGEN NV.: PRODUCT PORTFOLIO
  • TABLE 82. QIAGEN NV.: KEY STRATERGIES
  • TABLE 83. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 84. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 85. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 86. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 87. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 88. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 89. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 90. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED CANCER MEDICINE MARKET (2023-2032)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED CANCER MEDICINE MARKET
  • FIGURE 09. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PERSONALIZED CANCER MEDICINE MARKET BY REGION, 2022
  • FIGURE 16. U.S. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 17. CANADA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 18. MEXICO PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 19. GERMANY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 20. FRANCE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 21. UK PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 22. ITALY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 23. SPAIN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 24. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 25. JAPAN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 26. CHINA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 27. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 28. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 29. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 30. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: PERSONALIZED CANCER MEDICINE MARKET
  • FIGURE 37. TOP PLAYER POSITIONING, 2022
  • FIGURE 38. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 41. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 42. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 43. GENERAL ELECTRIC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 44. GENERAL ELECTRIC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. GENERAL ELECTRIC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 59. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)